{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:51:42Z","timestamp":1792032702249,"version":"4.4.0"},"reference-count":93,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Atherosclerotic cardiovascular disease (ASCVD) represents a major global health challenge, significantly contributing to mortality rates. This chronic inflammatory condition affecting blood vessels is intricately linked to hypercholesterolemia, with elevated levels of low-density lipoprotein cholesterol (LDL-C) recognized as a central and modifiable risk factor. The effectiveness of lipid-lowering therapy (LLT) in mitigating ASCVD risk is well established, with studies revealing a substantial reduction in major ischemic events correlating with LDL-C reduction. While statins, often combined with ezetimibe, remain fundamental in dyslipidemia management, a significant proportion of patients on statin therapy continue to experience cardiovascular events. Recent pharmacological advancements, driven by a deeper understanding of atherogenesis, have unveiled novel therapeutic targets and potent drugs. Notably, agents like bempedoic acid and proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors (evolocumab, alirocumab, inclisiran) have emerged as effective options to intensify LLT and achieve LDL-C goals, addressing limitations associated with statins, such as myopathy. Molecular insights into alternative pathways have spurred the investigation of emerging agents, offering promising perspectives for novel medications with efficacy comparable to established treatments, associated with advantages in cost and administration. This review provides a comprehensive overview of the evolving landscape of lipid-lowering strategies, highlighting the progress made in addressing ASCVD risk and the potential of upcoming therapies to further optimize cardiovascular prevention.<\/jats:p>","DOI":"10.3390\/jcm13051251","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T08:34:35Z","timestamp":1708590875000},"page":"1251","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1696-7053","authenticated-orcid":false,"given":"Federica","family":"Agnello","sequence":"first","affiliation":[{"name":"Division of Cardiology, Ospedale Umberto I, ASP 4 di Enna, 94100 Enna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Ingala","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Ospedale Umberto I, ASP 4 di Enna, 94100 Enna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8932-9045","authenticated-orcid":false,"given":"Giulia","family":"Laterra","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Ospedale Umberto I, ASP 4 di Enna, 94100 Enna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8429-1619","authenticated-orcid":false,"given":"Lorenzo","family":"Scalia","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Ospedale Umberto I, ASP 4 di Enna, 94100 Enna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4903-5437","authenticated-orcid":false,"given":"Marco","family":"Barbanti","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Ospedale Umberto I, ASP 4 di Enna, 94100 Enna, Italy"},{"name":"Faculty of Medicine and Surgery, Universit\u00e0 degli Studi di Enna \u201cKore\u201d, 94100 Enna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/14740338.2022.2036717","article-title":"Anti-inflammatory strategies for atherosclerotic artery disease","volume":"21","author":"Agnello","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global Burden of Cardiovascular Diseases and Risk actors, 1990\u20132019: Update from the GBD 2019 Study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","unstructured":"Emerging Risk Factors Collaboration, Di Angelantonio, E., Gao, P., Pennells, L., and Danesh, J. (2012). Lipid-related markers and cardiovascular disease prediction. JAMA, 307, 2499\u20132506."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., and Collins, R. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 376, 1670\u20131681.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-Analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1910355","article-title":"A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke","volume":"382","author":"Amarenco","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.jacc.2019.01.077","article-title":"Residual Inflammatory Risk in Patients with Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention","volume":"73","author":"Guedeney","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00392-019-01511-0","article-title":"Residual inflammatory risk in coronary heart disease: Incidence of elevated high-sensitive CRP in a real-world cohort","volume":"109","author":"Peikert","year":"2019","journal-title":"Clin. Res. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events: A Meta-Analysis of Statin Trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Aygun, S., and Tokgozoglu, L. (2022). Comparison of Current International Guidelines for the Management of Dyslipidemia. J. Clin. Med., 11.","DOI":"10.3390\/jcm11237249"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","article-title":"Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg\/dL with Rosuvastatin: The JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)","volume":"57","author":"Hsia","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/ijcp.12881","article-title":"Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: The evidence to date","volume":"70","author":"McCormack","year":"2016","journal-title":"Int. J. Clin. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/eurheartj\/ehaa1011","article-title":"Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: A Swedish nationwide cohort study","volume":"42","author":"Schubert","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Agnello, F., Mauro, M.S., Rochira, C., Landolina, D., Finocchiaro, S., Greco, A., Ammirabile, N., Raffo, C., Mazzone, P.M., and Spagnolo, M. (2023). PCSK9 inhibitors: Current status and emerging frontiers in lipid control. Expert Rev. Cardiovasc. Ther., 1\u201318.","DOI":"10.1080\/14779072.2023.2288169"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jacc.2015.01.036","article-title":"Impact of Statins on Serial Coronary Calcification During Atheroma Progression and Regression","volume":"65","author":"Puri","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jcmg.2018.04.015","article-title":"Effects of Statins on Coronary Atherosclerotic Plaques: The PARADIGM Study","volume":"11","author":"Lee","year":"2018","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/jcsm.12960","article-title":"Step-by-step diagnosis and management of the nocebo\/drucebo effect in statin-associated muscle symptoms patients: A position paper from the International Lipid Expert Panel(ILEP)","volume":"13","author":"Penson","year":"2022","journal-title":"J. Cachex- Sarcopenia Muscle"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e075837","DOI":"10.1136\/bmj-2023-075837","article-title":"Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: Secondary analysis of the randomised LODESTAR trial","volume":"383","author":"Lee","year":"2023","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2147\/VHRM.S33664","article-title":"Ezetimibe therapy: Mechanism of action and clinical update","volume":"8","author":"Toth","year":"2012","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials","volume":"223","author":"Morrone","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.amjcard.2004.02.060","article-title":"Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia","volume":"93","author":"Ballantyne","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: A convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.122.062557","article-title":"Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study","volume":"147","author":"Romero","year":"2023","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients with Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial","volume":"327","author":"Ueki","year":"2022","journal-title":"JAMA"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Grze\u015bk, G., Dorota, B., Wo\u0142owiec, \u0141., Wo\u0142owiec, A., Osiak, J., Kozakiewicz, M., and Banach, J. (2022). Safety of PCSK9 inhibitors. Biomed. Pharmacother., 156.","DOI":"10.1016\/j.biopha.2022.113957"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"101006","DOI":"10.1016\/j.plipres.2019.101006","article-title":"ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review","volume":"77","author":"Feng","year":"2019","journal-title":"Prog. Lipid Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jacl.2022.03.001","article-title":"Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials","volume":"16","author":"Laufs","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S2213-8587(23)00316-9","article-title":"Efficacy and safety of bempedoic acid among patients with and without diabetes: Prespecified analysis of the CLEAR Outcomes randomised trial","volume":"12","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2022.03.020","article-title":"Long-Term Safety and Efficacy of Bempedoic Acid in Patients with Atherosclerotic Cardiovascular Disease and\/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study)","volume":"174","author":"Ballantyne","year":"2022","journal-title":"Am. J. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Morris","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Basiak, M., Hachula, M., Kosowski, M., and Okopien, B. (2022). Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia. J. Clin. Med., 11.","DOI":"10.3390\/jcm11092542"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A Highly Durable RNAi Therapeutic Inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): Results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.122.063460","article-title":"Efficacy, Safety, and Tolerability of Inclisiran in Patients with Homozygous Familial Hypercholesterolemia: Results from the ORION-5 Randomized Clinical Trial","volume":"149","author":"Raal","year":"2024","journal-title":"Circulation"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Gareri, C., Polimeni, A., Giordano, S., Tamm\u00e8, L., Curcio, A., and Indolfi, C. (2022). Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias. J. Clin. Med., 11.","DOI":"10.3390\/jcm11133884"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","article-title":"Antisense inhibition of proprotein convertase subtilisin\/kexin type 9 reduces serum LDL in hyperlipidemic mice","volume":"48","author":"Graham","year":"2007","journal-title":"J. Lipid Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1053\/j.ajkd.2013.02.359","article-title":"Acute Kidney Injury During Therapy with an Antisense Oligonucleotide Directed Against PCSK9","volume":"62","author":"Swart","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/psp4.12866","article-title":"A case-study of model-informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II","volume":"11","author":"Nilsson","year":"2022","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"105562","DOI":"10.1016\/j.phrs.2021.105562","article-title":"New PCSK9 inhibitor miR-552-3p reduces LDL-C via enhancing LDLR in high fat diet-fed mice","volume":"167","author":"Ma","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ymthe.2018.10.016","article-title":"Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics","volume":"27","author":"Khoshnejad","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","article-title":"Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616","volume":"81","author":"Ballantyne","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jacl.2016.07.004","article-title":"A review of PCSK9 inhibition and its effects beyond LDL receptors","volume":"10","author":"Dixon","year":"2016","journal-title":"J. Clin. Lipidol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models","volume":"147","author":"Lee","year":"2023","journal-title":"Circulation"},{"key":"ref_55","unstructured":"(2023, December 10). VERVE-101: CRISPR-Based Gene Editing Therapy Shows Promise in Reducing LDL-C and PCSK9 Levels in Patients with HeFH\u2014American College of Cardiology. Available online: https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2023\/11\/08\/20\/14\/sun-445pm-heart1-aha-2023."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40119-020-00191-6","article-title":"Vaccines Targeting PSCK9 for the Treatment of Hyperlipidemia","volume":"9","author":"Toth","year":"2020","journal-title":"Cardiol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Galabova, G., Brunner, S., Winsauer, G., Juno, C., Wanko, B., Mairhofer, A., L\u00fchrs, P., Schneeberger, A., von Bonin, A., and Mattner, F. (2014). Peptide-Based Anti-PCSK9 Vaccines\u2014An Approach for Long-Term LDLc Management. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0114469"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.coi.2019.02.008","article-title":"Vaccination against atherosclerosis","volume":"59","author":"Kobiyama","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1093\/eurheartj\/ehab299","article-title":"PCSK9 vaccine: So near, yet so far!","volume":"42","author":"Sahebkar","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","article-title":"The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice","volume":"38","author":"Landlinger","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Momtazi-Borojeni, A.A., Jaafari, M.R., Banach, M., Gorabi, A.M., Sahraei, H., and Sahebkar, A. (2021). Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates. Vaccines, 9.","DOI":"10.3390\/vaccines9070749"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in Patients with Refractory Hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jamacardio.2023.2921","article-title":"Longer-Term Efficacy and Safety of Evinacumab in Patients with Refractory Hypercholesterolemia","volume":"8","author":"Rosenson","year":"2023","journal-title":"JAMA Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for Homozygous Familial Hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.jacadv.2023.100648","article-title":"The Long-Term Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia","volume":"2","author":"Raal","year":"2023","journal-title":"JACC Adv."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","article-title":"Evinacumab for Pediatric Patients with Homozygous Familial Hypercholesterolemia","volume":"149","author":"Wiegman","year":"2024","journal-title":"Circulation"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of Vupanorsen on Non\u2013High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients with Elevated Cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark","year":"2022","journal-title":"Circulation"},{"key":"ref_71","unstructured":"(2023, December 03). Pfizer and Lonis Announce Discontinuation of Vupanorsen Clinical Development Program|Pfizer. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-ionis-announce-discontinuation-vupanorsen."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"A15751","DOI":"10.1161\/circ.142.suppl_3.15751","article-title":"Abstract 15751: Pharmacodynamic Effect of ARO-ANG3, an Investigational RNA Interference Targeting Hepatic Angiopoietin-like Protein 3, in Patients with Hypercholesterolemia","volume":"142","author":"Watts","year":"2020","journal-title":"Circulation"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"A17120","DOI":"10.1161\/circ.148.suppl_1.17120","article-title":"Abstract 17120: ARO-ANG3, an Investigational RNAi Therapeutic, Silences the Expression of ANGPTL3 and Decreases Atherogenic Lipoproteins in Patients with Mixed Dyslipidemia: ARCHES-2 Study Results","volume":"148","author":"Watts","year":"2023","journal-title":"Circulation"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1172\/JCI117537","article-title":"Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol","volume":"94","author":"Inazu","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1056\/NEJM199011013231803","article-title":"Increased High-Density Lipoprotein Levels Caused by a Common Cholesteryl-Ester Transfer Protein Gene Mutation","volume":"323","author":"Inazu","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of Torcetrapib in Patients at High Risk for Coronary Events","volume":"357","author":"Barter","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1210\/en.2008-1512","article-title":"Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition","volume":"150","author":"Hu","year":"2009","journal-title":"Endocrinology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/eurheartj\/ehr348","article-title":"Torcetrapib impairs endothelial function in hypertension","volume":"33","author":"Simic","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"The HPS3\/TIMI55\u2013REVEAL Collaborative Group (2017). Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N. Engl. J. Med., 377, 1217\u20131227.","DOI":"10.1056\/NEJMoa1706444"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jacl.2023.05.098","article-title":"Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial","volume":"17","author":"Ballantyne","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease","volume":"146","author":"Giugliano","year":"2022","journal-title":"Circulation"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: The multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ahj.2023.08.012","article-title":"A review of polypills for the prevention of atherosclerotic cardiovascular disease","volume":"266","author":"Agnello","year":"2023","journal-title":"Am. Heart J."},{"key":"ref_91","first-page":"200198","article-title":"Residual cardiovascular risk, use of standard care treatments, and achievement of treatment goals in patients with cardiovascular disease","volume":"18","author":"Siniawski","year":"2023","journal-title":"Int. J. Cardiol. Cardiovasc. Risk Prev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12933-023-01826-3","article-title":"Effect of dual residual risk of cholesterol and inflammation on all-cause mortality in patients with cardiovascular disease","volume":"22","author":"Yang","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.amjcard.2023.04.036","article-title":"Eligibility to Intensified Antithrombotic Regimens for Secondary Prevention in Patients Who Underwent Percutaneous Coronary Intervention","volume":"199","author":"Greco","year":"2023","journal-title":"Am. J. Cardiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/5\/1251\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:03:13Z","timestamp":1760104993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/5\/1251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":93,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["jcm13051251"],"URL":"https:\/\/doi.org\/10.3390\/jcm13051251","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]}}}